newsfilter
← Latest News
Business Wire·

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

  • TibuSHIELD enrollment for tibulizumab in hidradenitis suppurativa is complete with 247 participants, exceeding targets, with topline data expected in Q4 2026.
  • TibuSURE enrollment for tibulizumab in systemic sclerosis is complete with 91 participants, exceeding targets, with topline data expected in H1 2027.
  • Zura plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by the end of 2026.
  • Zura holds $205.1 million in cash and cash equivalents as of June 30, 2026, sufficient to fund operations through at least the end of 2028.
  • Research and development expenses for the second quarter of 2026 were $20.7 million, an increase from $8.7 million in the same period of 2025.
  • General and administrative expenses for the second quarter of 2026 were $8.6 million, a decrease from $9.4 million in the same period of 2025.
  • Zura reported a net loss of $26.3 million, or $0.21 per share, for the second quarter of 2026, compared to a loss of $16.0 million, or $0.17 per share, in the same period of 2025.